TEVA-COTRIDIN 30 MG / 5 ML
PSEUDOEPHEDRINE HYDROCHLORIDE : 30 MG / 5 ML TRIPROLIDINE HYDROCHLORIDE : 2 MG / 5 ML CODEINE PHOSPHATE : 10 MG / 5 ML · DIN 02169126 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-COTRIDIN?
TEVA-COTRIDIN 30 MG / 5 ML contains PSEUDOEPHEDRINE HYDROCHLORIDE : 30 MG / 5 ML TRIPROLIDINE HYDROCHLORIDE : 2 MG / 5 ML CODEINE PHOSPHATE : 10 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02169126, held by TEVA CANADA LIMITED, supplied as SYRUP for ORAL administration. Health Canada currently lists it as marketed, status dated 05-Mar-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-COTRIDIN used for?
Temporary relief of coughs associated with allergy or the common cold in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is TEVA-COTRIDIN called?
The same molecule, COMBINATIONS, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ekyflogyl | Latin | Iceland |
| OTIPAX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02169126 |
|---|---|
| Brand name | TEVA-COTRIDIN |
| Generic / active ingredient | PSEUDOEPHEDRINE HYDROCHLORIDE : 30 MG / 5 ML TRIPROLIDINE HYDROCHLORIDE : 2 MG / 5 ML CODEINE PHOSPHATE : 10 MG / 5 ML |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 30 MG / 5 ML |
| Dosage form | SYRUP |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | R05DA20 COMBINATIONS |
| AHFS class | 04:04.20 ; 48:08.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Mar-2018 |
| Original market date | 1996-07-30 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02169126 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2169126 |
| Brand name | TEVA-COTRIDIN |
| Active ingredient / INN | PSEUDOEPHEDRINE HYDROCHLORIDE : 30 MG / 5 ML TRIPROLIDINE HYDROCHLORIDE : 2 MG / 5 ML CODEINE PHOSPHATE : 10 MG / 5 ML |
| ATC code | R05DA20 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R05 |
| AHFS class | 04:04.20 ; 48:08.00 |
| Health Canada schedule | NARCOTICS (CDSA I) |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it administered?
Adults: 5 mL every 4 to 6 hours. Do not exceed 4 doses (20 mL) in 24 hours. Use the lowest effective dose for the shortest duration. Seek medical advice if symptoms persist >3 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (referenced in section 10, but specific temperature range not listed in snippet).
How is it supplied?
Not explicitly detailed in provided text (referenced in section 12, but specific container sizes not listed in snippet).
Which pack is which?
| Strength on the label | 30 MG / 5 ML |
|---|---|
| Dosage form | SYRUP |
| Route | ORAL |
| Packaging as described in the monograph | Not explicitly detailed in provided text (referenced in section 12, but specific container sizes not listed in snippet). |
| Storage | Not explicitly detailed in provided text (referenced in section 10, but specific temperature range not listed in snippet). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Contraindications
Patients <18 years; pregnant/breastfeeding women; CYP2D6 ultra-rapid metabolizers; MAOIs use; asthma; respiratory depression; hypertension; coronary artery disease; severe hepatic/renal impairment.
Warnings and precautions
Risk of addiction, abuse, misuse, and fatal respiratory depression. Concomitant use with benzodiazepines or alcohol may result in coma or death. May impair ability to drive or operate machinery.
What can be used instead?
Other Canadian products sharing ATC code R05DA20 COMBINATIONS. 11 of 165 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BENYLIN FOR CHILDREN COUGH & COLD | 7.5 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 01944746 |
| COLDASIDE COUGH & COLD | 4 MG | TABLET | TANTA PHARMACEUTICALS INC | MARKETED | DIN 02309440 |
| JACK & JILL BEDTIME HONEY COUGH & COLD | 7.5 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | DIN 02522969 |
| JACK & JILL MULTI-SYMPTOM COLD & COUGH | 7.5 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | DIN 02533626 |
| NYQUIL COUGH DM + CONGESTION | 6.25 MG / 15 ML | SYRUP | PROCTER & GAMBLE INC | MARKETED | DIN 02503611 |
| NYQUIL KIDS | 5 MG / 15 ML | SYRUP | PROCTER & GAMBLE INC | MARKETED | DIN 02520419 |
| NYQUIL KIDS COUGH & COLD | 2 MG / 15 ML | SYRUP | PROCTER & GAMBLE INC | MARKETED | DIN 02273330 |
| ROBITUSSIN CHILDREN'S COUGH & COLD BEDTIME | 5 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | DIN 02394707 |
| ROBITUSSIN CHILDREN'S COUGH AND COLD | 7.5 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | DIN 02044013 |
| ROBITUSSIN HONEY COUGH & COLD NIGHTTIME | 12.5 MG / 20 ML | SYRUP | HALEON CANADA ULC | MARKETED | DIN 02485443 |
Who else supplies COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does COMBINATIONS cost around the world?
COMBINATIONS is listed on 4 national price registers Nexara tracks, across 8 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Hungary | producer price (ex-factory) | 5 | 5 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
| Luxembourg | reimbursement | 1 | 1 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.